The study of pembrolizumab with ipilimumab as second-line therapy for advanced melanoma provided compelling evidence that the combination of PD-1 and CTLA4 is a safe and effective treatment approach in the PD-1–refractory patient population [20]. This evidence concerns the gene PDCD1 and melanoma.